MedTrace Logo

Anti-Inflammatory Lipid Mediators in Asthma

NCT03680976 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-09-21

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the efficacy and safety of 10-nitro-9(E)-octadec-9-enoic acid (CXA-10) in obese adult asthmatics. The study's hypothesis is that 150 mg/day of CXA-10 for 12 weeks will alleviate obesity-related airway hyper-reactivity in obese adult asthmatics.

Conditions

Interventions

DRUG

CXA-10

Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.

DRUG

Placebo

Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule

Sponsors & Collaborators

  • Sally E. Wenzel MD

    lead OTHER

Principal Investigators

  • Sally E Wenzel, MD · The University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2021-04-30
Completion
2021-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03680976 on ClinicalTrials.gov